Semaglutide does not directly damage fertility, but it changes three things that drive it: ovulation, cycle regularity, and contraceptive reliability. If you're on Ozempic, Wegovy, or planning to start, here's what the mechanism actually does and what to change about your routine before you try to conceive.
TL;DR
- Semaglutide and fertility interact mainly through weight loss and ovulation, not direct hormone suppression.
- Wegovy and Ozempic labels call for stopping at least 2 months before a planned pregnancy in 2026.
- Oral semaglutide (Rybelsus) can blunt oral contraceptive absorption — use backup birth control.
- Weight loss on semaglutide often restores ovulation in women with PCOS-driven infertility. Verdict: plan the washout, don't wing it.
- Semaglutide affects fertility mainly through weight-loss-driven ovulation, not direct hormone suppression.
- Wegovy and Ozempic labels call for stopping at least 2 months before a planned pregnancy.
- Oral semaglutide (Rybelsus) can blunt oral contraceptive absorption, especially in the first four weeks after a dose increase.
- A 5-10% body weight loss can restore regular ovulation in PCOS-related infertility.
- The drug's roughly 7-day half-life means about five weeks are needed to fully clear it — well short of the 2-month washout window.
Why this matters
Most of the internet chatter about semaglutide and fertility comes from anecdotal "Ozempic baby" reports, not from the drug directly stimulating ovulation. What's actually happening is more mundane and more useful: rapid weight loss and improved insulin sensitivity can restore ovulation in women whose cycles stopped or went irregular because of excess weight or insulin resistance, particularly with PCOS.
Semaglutide itself is not a hormone. It's a GLP-1 receptor agonist that slows gastric emptying and blunts appetite. The half-life is about 7 days, which means it takes roughly five weeks to clear the body after your last dose — a number that matters more than most patients realize when they're planning conception.
The FDA label for Wegovy recommends discontinuing the medication at least 2 months before a planned pregnancy, both because of the clearance timeline and because reproductive toxicity showed up in animal studies at high doses. That's not the same as proof of harm in humans — no controlled human fertility trials exist — but it's the standard your clinician should be working from in 2026.
What you'll need
- A cycle-tracking app or paper log started at least one cycle before beginning semaglutide
- A documented contraception plan, especially if you're on oral semaglutide (Rybelsus)
- Baseline labs: fasting insulin, A1c, and a hormone panel if cycles are already irregular
- A clinician who will actually review dose escalation against your cycle, not just your weight
- A written washout timeline if pregnancy is a near-term goal
The steps
1. Track your cycle before you start
You can't tell whether semaglutide changed your cycle if you don't know your baseline. Log cycle length, flow, and any missed periods for at least one full cycle before your first dose. Common mistake: starting the medication and only noticing a missed period two months later with no reference point.
2. Confirm your contraception method on day one
Oral semaglutide slows gastric emptying enough to reduce peak absorption of other oral medications, including combined oral contraceptives, particularly during the first four weeks or after a dose increase. If you're on Rybelsus and the pill, add a barrier method or switch to a non-oral contraceptive for at least one month after any dose change. Injectable semaglutide (Ozempic, Wegovy) carries less of this interaction concern, but talk it through anyway. Common mistake: assuming injectable and oral GLP-1s carry identical contraceptive risk — they don't.
Injectable vs Oral Semaglutide: Contraceptive Interaction
Based on absorption mechanism differences
| Formulation | Contraceptive Interaction Risk | What to Do |
|---|---|---|
| Oral semaglutide (Rybelsus) | Slows gastric emptying, may reduce absorption of oral contraceptives, especially in the first four weeks or after a dose increase | Add a barrier method or switch to a non-oral contraceptive for at least one month after any dose change |
| Injectable semaglutide (Ozempic, Wegovy) | Carries less of this interaction concern | Discuss with your clinician anyway |
3. Expect ovulation to shift as weight drops
In women with obesity-related anovulation or PCOS, a 5-10% body weight loss can restore regular ovulation within a few months. This is the actual mechanism behind most semaglutide-and-fertility stories: weight loss lowers circulating androgens and improves insulin sensitivity, which is exactly what a GLP-1 protocol for PCOS is built to influence. Expected outcome: cycles that were 45+ days may shorten toward 28-35 days over 3-6 months.
In women with obesity-related anovulation or PCOS, a 5-10% body weight loss can restore regular ovulation within a few months — cycles that were 45+ days may shorten toward 28-35 days over 3-6 months.
4. Time labs around your cycle, not the calendar
Hormone labs drawn on the wrong cycle day give misleading numbers, especially estradiol and progesterone. If your clinician is tracking how long semaglutide takes to work alongside your reproductive labs, coordinate draw dates with cycle day 3 or day 21 depending on what's being measured. Common mistake: drawing progesterone on a random weekday and comparing it against a textbook range that assumes a known ovulation date.
5. Match dose escalation to how your body is responding
Most semaglutide protocols escalate every 4 weeks, moving from 0.25 mg up toward maintenance doses over roughly 16 to 20 weeks. Rapid escalation can trigger nausea and appetite suppression severe enough to disrupt normal cycling in some patients. Reviewing the GLP-1 dose escalation schedule with your clinician before each step lets you flag cycle changes as they happen rather than after three missed periods. Expected outcome: steadier weight loss and fewer surprise cycle gaps than aggressive titration.
6. Loop in a fertility specialist early if conception is a near-term goal
If you're actively trying to conceive within the next 6 months, don't wait until you're already pregnant to mention semaglutide. A reproductive endocrinologist or OB can coordinate the washout window with your weight-loss clinician so you're not choosing between momentum and safety at the last minute. Common mistake: stopping semaglutide abruptly the week of a positive pregnancy test instead of planning the taper in advance.
7. Reassess menstrual changes at every check-in, not just at intake
Cycle length, flow changes, and new symptoms like breast tenderness or spotting deserve a mention at every follow-up, not just the first visit. A first telehealth weight loss consultation usually covers baseline reproductive history, but ongoing visits are where dose-and-cycle correlations actually get caught. Common mistake: treating a single skipped period as an emergency instead of a data point across several cycles.
Troubleshooting
- Periods became irregular after starting semaglutide. Rapid weight loss itself can temporarily disrupt cycles even when it's ultimately restoring ovulation. Give it two to three cycles before assuming a problem, and flag it if bleeding is heavier or more frequent than every 21 days.
- Birth control pill seems less reliable on Rybelsus. Switch to a backup method or a non-oral contraceptive for at least the first month after any dose increase, since delayed gastric emptying can blunt oral drug absorption.
- Trying to conceive but still on semaglutide. Plan a stop date at least 2 months before your target conception window per current label guidance, and confirm the timeline with your clinician rather than stopping cold on your own schedule.
- Cycles didn't improve despite significant weight loss. Insulin resistance and hormone imbalance sometimes need direct lab-guided treatment beyond weight loss alone — a full hormone and metabolic panel is the next move, not more time on the scale.
- Nausea from dose escalation is masking whether your cycle changed. Severe GI side effects can themselves disrupt cycle regularity through stress and reduced intake; managing the side effect often resolves the apparent cycle issue too.
Tools and resources
- Cycle-tracking app with at least 3 months of history before and after starting semaglutide
- Baseline fasting insulin, A1c, and hormone panel drawn before your first dose
- A documented washout timeline shared between your weight-loss clinician and OB or fertility specialist
- Guidance on finding a weight loss doctor who prescribes GLP-1s if you're switching providers mid-protocol
Talk to a clinician before your next dose
Review your cycle history and contraception plan with a licensed GoodLife Health clinician.
[Explore membership plan](https://goodlifehealth.ai/learning-center/health-membership-plan-for-weight-loss-and-hormone-care)
What to do next
If your cycles have already changed on semaglutide, the next move isn't guesswork — it's a lab-guided conversation with a clinician who reviews both your metabolic panel and your reproductive history together, not two separate providers working from different charts.
Plan backward from your target conception month, not forward from your last dose.
FAQ
Does semaglutide cause infertility?
No. Semaglutide is not shown to cause infertility in humans; most fertility changes on the drug come from weight loss and improved insulin sensitivity restoring ovulation, especially in women with PCOS or obesity-related anovulation.
How long before pregnancy should you stop semaglutide?
Current label guidance for Wegovy recommends stopping at least 2 months before a planned pregnancy, based on the drug's roughly 7-day half-life and animal reproductive toxicity data.
Can semaglutide make birth control pills less effective?
Oral semaglutide (Rybelsus) can slow gastric emptying enough to reduce absorption of other oral drugs, including combined oral contraceptives. A backup or non-oral method is the safer default during the first month of any dose change.
Does semaglutide help with PCOS-related infertility?
It can indirectly, by lowering weight and improving insulin resistance, both of which are drivers of anovulation in PCOS. It is not FDA-approved specifically for fertility treatment.
Is it safe to get pregnant while on semaglutide?
Semaglutide is not recommended during pregnancy. If you conceive while on it, contact your clinician immediately to discuss stopping the medication and monitoring the pregnancy.
Why did my period become irregular after starting semaglutide?
Rapid weight loss itself can temporarily disrupt cycle regularity, even when the underlying trend is toward restored ovulation. Most patients see cycles stabilize within two to three cycles.
Does tirzepatide affect fertility the same way as semaglutide?
Both are GLP-1-class medications with similar mechanisms, so the weight-loss-driven ovulation effect and the pre-conception washout guidance apply similarly, though tirzepatide's half-life and dosing schedule differ.
Should I tell my fertility doctor I'm on semaglutide?
Yes, immediately and at every visit. Coordinating the washout timeline between your weight-loss clinician and fertility specialist prevents last-minute scrambling near a conception window.
One last thing
The detail most patients miss isn't the drug — it's the timeline. A 7-day half-life sounds fast until you realize it takes about five half-lives, or roughly five weeks, just to clear the drug, and the FDA-recommended washout before conception in 2026 is still double that. Plan backward from your target conception month, not forward from your last dose.
Related guides
- GLP-1 therapy for PCOS beyond weight loss
- How long semaglutide takes to work
- GLP-1 dosing schedule and dose escalation
- What to expect at your first telehealth weight loss consultation
- Hormone optimization for women in perimenopause
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/